AstraZeneca to build plant in Singapore

Squeaky-clean reputation: A general view of the Jurong Tuas industrial area in Singapore. AstraZeneca says the city-state is one of the world’s most attractive countries for investment, given its reputation for excellence in complex manufacturing. — AFP

SINGAPORE: Global biopharmaceutical company AstraZeneca intends to build a US$1.5bil manufacturing facility in Singapore, the company says.

It aims to begin the designing and construction of the facility by the end of 2024, and targets it to be operationally ready from 2029.